DPLO up +3.12% percent right now. $DPLO High is at 21.56 and the Low 20.66 with current volume of 113,896.
Recent News posted below.
DPLO Dplo Recent Headline News
Diplomat Pharmacy EPS of $0.15
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:45PM CST
DPLO: 21.50 (+0.98)
Diplomat Announces 3rd Quarter Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2014. All comparisons, unless otherwise noted, are to the quarter ended September 30, 2013.
DPLO: 21.50 (+0.98)
A Gracious Opening For Diplomat Pharmacy Investors
Don Dion - at Seeking Alpha - Thu Nov 06, 3:43PM CST
ESRX: 77.75 (-0.24), DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), WAG: 67.41 (-0.37)
Diplomat hires Martino Luu as vice president of innovation and process improvement
M2 - Thu Nov 06, 7:28AM CST
Pharmacy Diplomat Pharmacy (NYSE
PLO) disclosed on Wednesday that it has appointed Martino Luu, RPh, as vice president of its innovation and process improvement.
DPLO: 21.50 (+0.98)
Diplomat names Martino Luu vice president of innovation and process improvement
PR Newswire - Wed Nov 05, 3:48PM CST
Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced the addition of Martino Luu, RPh, to their senior leadership team as vice president of innovation and process improvement. In this role, Luu will work with various Diplomat business units to evaluate current processes and make recommendations for improvements to increase efficiency. "Martino will be instrumental in assisting with the implementation of recommended process changes," Diplomat President Gary Kadlec said. "He brings significant industry knowledge to Diplomat and has the experience necessary to drive efficiencies that address the challenges of the specialty pharmacy space."
DPLO: 21.50 (+0.98)
Diplomat named to ICIC and Fortune's Inner City 100; among the nation's fastest-growing inner city businesses
PR Newswire - Wed Nov 05, 7:45AM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, is proud to announce that the company has been named to the Inner City 100 list. The annual competition, held by Initiative for a Competitive Inner City, seeks to celebrate urban entrepreneurship by recognizing the fastest-growing businesses headquartered in America's inner cities, as measured by revenue growth between 2009 and 2013.
DPLO: 21.50 (+0.98)
American Homecare Federation celebrates 25 years of service to the bleeding disorders community
PR Newswire - Tue Nov 04, 3:32PM CST
American Homecare Federation, a Diplomat company (NYSE: DPLO), is celebrating 25 years of business this year. Headquartered in Enfield, Connecticut, AHF is a specialty pharmacy that provides homecare pharmacy services to patients living with hemophilia, von Willebrand disease and other bleeding disorders.
DPLO: 21.50 (+0.98)
Diplomat Recognized as One of Michigan's Best and Brightest in Wellness
PR Newswire - Tue Nov 04, 3:05PM CST
Diplomat, the nation's largest independent specialty pharmacy, announced that it has been selected as one of Michigan's Best and Brightest in Wellness. The awards program honors companies and organizations that recognize and celebrate quality and excellence in health and wellness. This is the second consecutive year that Diplomat has been honored.
DPLO: 21.50 (+0.98)
U.S. IPO Weekly Recap: Boots, Barrels And Busts
Renaissance Capital IPO Research - Seeking Alpha - Sun Nov 02, 4:14AM CST
Four IPOs raised $1.2 billion during the past week, the third week in a row with five or less. Year-to-date, the IPO market has seen 235 initial public offerings raise $75 billion. The week's energy, health care, finance and consumer IPOs saw...
MOLG: 8.06 (+0.53), SHLX: 36.66 (+1.04), DPLO: 21.50 (+0.98), BOOT: 18.90 (+0.90), FSAM: 13.57 (-0.24), ATRA: 27.78 (+1.36), SIEN: 17.73 (-0.27)
Diplomat to Release Third Quarter Operating Results and Host Conference Call on Monday, November 10, 2014
PR Newswire - Mon Oct 27, 3:18PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, will release its third quarter 2014 operating results on Monday, November 10, 2014 after market close, with a conference call to follow at 5:00p.m. Eastern Time.
DPLO: 21.50 (+0.98)
Diplomat to Participate in 2014 Credit Suisse Healthcare Conference
PR Newswire - Mon Oct 27, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at the upcoming 2014 Credit Suisse Healthcare Conference in Phoenix, AZ.
DPLO: 21.50 (+0.98)
Harvoni® (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults; Diplomat to distribute
PR Newswire - Wed Oct 22, 3:53PM CDT
U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni® (ledipasvir/sofosbuvir) product was approved for the treatment of chronic hepatitis C, genotype 1 infection in adults. Harvoni® is the first oral combination therapy approved for the treatment of hepatitis C and is also the first treatment regimen that does not require administration with pegylated interferon or ribavirin.
DPLO: 21.50 (+0.98)
Diplomat Pharmacy Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
PR Newswire - Thu Oct 16, 1:23PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, today announced the closing of its initial public offering of 15,333,333 shares of common stock at an initial public offering price of $13.00 per share, which included 2,000,000 shares sold pursuant to the full exercise of the underwriters' over-allotment option. Diplomat sold 11,000,000 shares of common stock and certain selling shareholders of Diplomat sold 4,333,333 shares of common stock. The company's common stock is listed on the New York Stock Exchange under the symbol "DPLO."
DPLO: 21.50 (+0.98)
Diplomat Pharmacy to distribute Esbriet, shares jump
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:43AM CDT
DPLO: 21.50 (+0.98)
Esbriet® (pirfenidone) receives FDA approval under 'breakthrough status'; Diplomat to distribute
PR Newswire - Thu Oct 16, 8:32AM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced today that it has a contract to distribute Esbriet (pirfenidone), which was approved Oct. 15, 2014 by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. In addition to the breakthrough therapy designation, Esbriet was also granted the orphan drug designation and received priority review.
DPLO: 21.50 (+0.98)
Diplomat Pharmacy: Now Filling Prescriptions For Capital Gains
Dallas Salazar - Seeking Alpha - Wed Oct 15, 5:30AM CDT
I know the market is in panic mode. I know the market is in absolute free-fall. I know the punch bowl might have just been taken away from a punch drunk mass of traders, and that the hangover headache of reality might be setting in for the...
DPLO: 21.50 (+0.98)
Diplomat Pharmacy, Dave & Buster's Surge In Debuts
at Investor's Business Daily - Fri Oct 10, 12:25PM CDT
Diplomat Pharmacy and Dave & Buster's Entertainment didn't play around in their first day of trading, attracting investors despite dismal overall performance from the major stock indexes. Diplomat Pharmacy (DPLO) priced its initial public offering...
DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), PLAY: 22.00 (-0.06), BWLD: 162.15 (+2.92), WAG: 67.41 (-0.37)
Diplomat Pharmacy Prices Its Initial Public Offering
PR Newswire - Thu Oct 09, 6:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, today announced the pricing of its initial public offering of 13,333,333 shares of common stock at a price to the public of $13.00 per share. The shares are expected to begin trading on the New York Stock Exchange under the symbol "DPLO" on October 10, 2014. Diplomat is selling 10,000,000 shares of common stock and certain selling shareholders of Diplomat are selling 3,333,333 shares of common stock. The Company and selling shareholders each have granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock (an aggregate of 2,000,000 shares of common stock) to cover over-allotments, if any.
DPLO: 21.50 (+0.98)
These 3 Upcoming IPOs Have Strong Investor Interest
at Investor's Business Daily - Tue Oct 07, 4:35PM CDT
HubSpot, a provider of a cloud-based marketing and sales software platform, raised its proposed IPO price, suggesting strong interest from institutional investors. HubSpot (HUBS) increased its proposed price to a range of 22 to 24, up from 19 to 21,...
ESRX: 77.75 (-0.24), DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), MKTO: 33.63 (+0.86), PLAY: 22.00 (-0.06), WAG: 67.41 (-0.37), HUBS: 36.39 (-0.13)
IPO Calendar: HubSpot, Dave & Buster's Among 8 IPOs
at Investor's Business Daily - Mon Oct 06, 1:15PM CDT
Eight IPOs slated for this week are a mix of tech, health care, finance and consumer offerings that, combined, plan to raise $1.3 billion. They follow 11 initial public offerings last week. The 59 U.S. IPOs in Q3 raised $37 billion, the most proceeds...
DPLO: 21.50 (+0.98), USDP: 16.75 (unch), VBTX: 14.87 (+0.27), MOLG: 8.06 (+0.53), ESRX: 77.75 (-0.24), SAGE: 33.77 (-3.22), MRNS: 6.90 (-0.11), OMAM: 15.31 (-0.14), CVS: 89.61 (+0.42), PLAY: 22.00 (-0.06), NSIG: (), WAG: 67.41 (-0.37), BABA: 114.84 (-4.31), HUBS: 36.39 (-0.13)
Recent News posted below.
DPLO Dplo Recent Headline News
Diplomat Pharmacy EPS of $0.15
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:45PM CST
DPLO: 21.50 (+0.98)
Diplomat Announces 3rd Quarter Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2014. All comparisons, unless otherwise noted, are to the quarter ended September 30, 2013.
DPLO: 21.50 (+0.98)
A Gracious Opening For Diplomat Pharmacy Investors
Don Dion - at Seeking Alpha - Thu Nov 06, 3:43PM CST
ESRX: 77.75 (-0.24), DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), WAG: 67.41 (-0.37)
Diplomat hires Martino Luu as vice president of innovation and process improvement
M2 - Thu Nov 06, 7:28AM CST
Pharmacy Diplomat Pharmacy (NYSE
PLO) disclosed on Wednesday that it has appointed Martino Luu, RPh, as vice president of its innovation and process improvement. DPLO: 21.50 (+0.98)
Diplomat names Martino Luu vice president of innovation and process improvement
PR Newswire - Wed Nov 05, 3:48PM CST
Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced the addition of Martino Luu, RPh, to their senior leadership team as vice president of innovation and process improvement. In this role, Luu will work with various Diplomat business units to evaluate current processes and make recommendations for improvements to increase efficiency. "Martino will be instrumental in assisting with the implementation of recommended process changes," Diplomat President Gary Kadlec said. "He brings significant industry knowledge to Diplomat and has the experience necessary to drive efficiencies that address the challenges of the specialty pharmacy space."
DPLO: 21.50 (+0.98)
Diplomat named to ICIC and Fortune's Inner City 100; among the nation's fastest-growing inner city businesses
PR Newswire - Wed Nov 05, 7:45AM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, is proud to announce that the company has been named to the Inner City 100 list. The annual competition, held by Initiative for a Competitive Inner City, seeks to celebrate urban entrepreneurship by recognizing the fastest-growing businesses headquartered in America's inner cities, as measured by revenue growth between 2009 and 2013.
DPLO: 21.50 (+0.98)
American Homecare Federation celebrates 25 years of service to the bleeding disorders community
PR Newswire - Tue Nov 04, 3:32PM CST
American Homecare Federation, a Diplomat company (NYSE: DPLO), is celebrating 25 years of business this year. Headquartered in Enfield, Connecticut, AHF is a specialty pharmacy that provides homecare pharmacy services to patients living with hemophilia, von Willebrand disease and other bleeding disorders.
DPLO: 21.50 (+0.98)
Diplomat Recognized as One of Michigan's Best and Brightest in Wellness
PR Newswire - Tue Nov 04, 3:05PM CST
Diplomat, the nation's largest independent specialty pharmacy, announced that it has been selected as one of Michigan's Best and Brightest in Wellness. The awards program honors companies and organizations that recognize and celebrate quality and excellence in health and wellness. This is the second consecutive year that Diplomat has been honored.
DPLO: 21.50 (+0.98)
U.S. IPO Weekly Recap: Boots, Barrels And Busts
Renaissance Capital IPO Research - Seeking Alpha - Sun Nov 02, 4:14AM CST
Four IPOs raised $1.2 billion during the past week, the third week in a row with five or less. Year-to-date, the IPO market has seen 235 initial public offerings raise $75 billion. The week's energy, health care, finance and consumer IPOs saw...
MOLG: 8.06 (+0.53), SHLX: 36.66 (+1.04), DPLO: 21.50 (+0.98), BOOT: 18.90 (+0.90), FSAM: 13.57 (-0.24), ATRA: 27.78 (+1.36), SIEN: 17.73 (-0.27)
Diplomat to Release Third Quarter Operating Results and Host Conference Call on Monday, November 10, 2014
PR Newswire - Mon Oct 27, 3:18PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, will release its third quarter 2014 operating results on Monday, November 10, 2014 after market close, with a conference call to follow at 5:00p.m. Eastern Time.
DPLO: 21.50 (+0.98)
Diplomat to Participate in 2014 Credit Suisse Healthcare Conference
PR Newswire - Mon Oct 27, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at the upcoming 2014 Credit Suisse Healthcare Conference in Phoenix, AZ.
DPLO: 21.50 (+0.98)
Harvoni® (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults; Diplomat to distribute
PR Newswire - Wed Oct 22, 3:53PM CDT
U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni® (ledipasvir/sofosbuvir) product was approved for the treatment of chronic hepatitis C, genotype 1 infection in adults. Harvoni® is the first oral combination therapy approved for the treatment of hepatitis C and is also the first treatment regimen that does not require administration with pegylated interferon or ribavirin.
DPLO: 21.50 (+0.98)
Diplomat Pharmacy Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
PR Newswire - Thu Oct 16, 1:23PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, today announced the closing of its initial public offering of 15,333,333 shares of common stock at an initial public offering price of $13.00 per share, which included 2,000,000 shares sold pursuant to the full exercise of the underwriters' over-allotment option. Diplomat sold 11,000,000 shares of common stock and certain selling shareholders of Diplomat sold 4,333,333 shares of common stock. The company's common stock is listed on the New York Stock Exchange under the symbol "DPLO."
DPLO: 21.50 (+0.98)
Diplomat Pharmacy to distribute Esbriet, shares jump
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:43AM CDT
DPLO: 21.50 (+0.98)
Esbriet® (pirfenidone) receives FDA approval under 'breakthrough status'; Diplomat to distribute
PR Newswire - Thu Oct 16, 8:32AM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced today that it has a contract to distribute Esbriet (pirfenidone), which was approved Oct. 15, 2014 by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. In addition to the breakthrough therapy designation, Esbriet was also granted the orphan drug designation and received priority review.
DPLO: 21.50 (+0.98)
Diplomat Pharmacy: Now Filling Prescriptions For Capital Gains
Dallas Salazar - Seeking Alpha - Wed Oct 15, 5:30AM CDT
I know the market is in panic mode. I know the market is in absolute free-fall. I know the punch bowl might have just been taken away from a punch drunk mass of traders, and that the hangover headache of reality might be setting in for the...
DPLO: 21.50 (+0.98)
Diplomat Pharmacy, Dave & Buster's Surge In Debuts
at Investor's Business Daily - Fri Oct 10, 12:25PM CDT
Diplomat Pharmacy and Dave & Buster's Entertainment didn't play around in their first day of trading, attracting investors despite dismal overall performance from the major stock indexes. Diplomat Pharmacy (DPLO) priced its initial public offering...
DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), PLAY: 22.00 (-0.06), BWLD: 162.15 (+2.92), WAG: 67.41 (-0.37)
Diplomat Pharmacy Prices Its Initial Public Offering
PR Newswire - Thu Oct 09, 6:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, today announced the pricing of its initial public offering of 13,333,333 shares of common stock at a price to the public of $13.00 per share. The shares are expected to begin trading on the New York Stock Exchange under the symbol "DPLO" on October 10, 2014. Diplomat is selling 10,000,000 shares of common stock and certain selling shareholders of Diplomat are selling 3,333,333 shares of common stock. The Company and selling shareholders each have granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock (an aggregate of 2,000,000 shares of common stock) to cover over-allotments, if any.
DPLO: 21.50 (+0.98)
These 3 Upcoming IPOs Have Strong Investor Interest
at Investor's Business Daily - Tue Oct 07, 4:35PM CDT
HubSpot, a provider of a cloud-based marketing and sales software platform, raised its proposed IPO price, suggesting strong interest from institutional investors. HubSpot (HUBS) increased its proposed price to a range of 22 to 24, up from 19 to 21,...
ESRX: 77.75 (-0.24), DPLO: 21.50 (+0.98), CVS: 89.61 (+0.42), MKTO: 33.63 (+0.86), PLAY: 22.00 (-0.06), WAG: 67.41 (-0.37), HUBS: 36.39 (-0.13)
IPO Calendar: HubSpot, Dave & Buster's Among 8 IPOs
at Investor's Business Daily - Mon Oct 06, 1:15PM CDT
Eight IPOs slated for this week are a mix of tech, health care, finance and consumer offerings that, combined, plan to raise $1.3 billion. They follow 11 initial public offerings last week. The 59 U.S. IPOs in Q3 raised $37 billion, the most proceeds...
DPLO: 21.50 (+0.98), USDP: 16.75 (unch), VBTX: 14.87 (+0.27), MOLG: 8.06 (+0.53), ESRX: 77.75 (-0.24), SAGE: 33.77 (-3.22), MRNS: 6.90 (-0.11), OMAM: 15.31 (-0.14), CVS: 89.61 (+0.42), PLAY: 22.00 (-0.06), NSIG: (), WAG: 67.41 (-0.37), BABA: 114.84 (-4.31), HUBS: 36.39 (-0.13)
